Stoke Therapeutics: Kaye plans $38.4M share sale

The proposed sales are described as following a cashless exercise of options under a registered plan, beginning October 21, 2026.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) is named in a Rule 144 notice by former affiliate Edward Kaye for a planned sale of 1,496,042 common shares, with an aggregate market value of $38,418,358.56. The notice says the sales are to follow a cashless exercise of options under a registered plan, commencing October 21, 2026.

Key Figures

Planned sale: 1,496,042 shares Aggregate market value: $38,418,358.56 Shares outstanding: 64,526,242 shares +2 more

5 metrics

Planned sale 1,496,042 shares Stoke Therapeutics common shares; sales commencing October 21, 2026

Aggregate market value $38,418,358.56 Planned sale of common shares

Shares outstanding 64,526,242 shares Stoke Therapeutics common shares

Prior sale 12,567 shares Common shares sold August 14, 2026

Prior sale aggregate value $402,521.01 Common shares sold August 14, 2026

Key Terms

Rule 144, cashless exercise, registered plan, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"cashless exercise of options and subsequent sales"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

registered plan financial

"Exercise of Options Under a Registered Plan"

A registered plan is a savings or investment account that a government recognizes for special tax treatment and rules, such as limits on how much you can put in and conditions for withdrawals. For investors it matters because those rules change how much of your gains are taxed, how quickly your money can be accessed and what strategies make sense — like a labeled jar that gives tax breaks but comes with rules about when and how you can take the money out.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many STOK shares did Edward Kaye plan to sell?

Edward Kaye reported a planned sale of 1,496,042 Stoke Therapeutics common shares, with an aggregate market value of $38,418,358.56. The notice says sales would commence October 21, 2026.

What prior STOK share sales did Edward Kaye report?

Edward Kaye reported selling 12,567 common shares on August 14, 2026, with an aggregate value of $402,521.01. The form lists this sale among securities sold during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 04:51 PM EDT Accepted by SEC EDGAR 10/21/2026 - 04:42 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001522780
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	STOKE THERAPEUTICS, INC.
SEC File Number	001-38938
Address of Issuer	45 Wiggins Ave Bedford MASSACHUSETTS 01730
Phone	781-430-8200
Name of Person for Whose Account the Securities are To Be Sold	EDWARD KAYE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1496042	38418358.56	64526242	10/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			27441	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			15360	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			51498	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			416884	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			88817	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			9876	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			187124	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			303083	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			4917	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			67789	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			3	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			186375	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			92321	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			7054	10/21/2026	Cash
Common	10/21/2026	Exercise of Options Under a Registered Plan	Issuer			37500	10/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Edward Kaye 45 Wiggins Ave Bedford MA 01730	Common	08/14/2026	12567	402521.01

144: Remarks and Signature

Remarks	This Form 144 is being filed for the cashless exercise of options and subsequent sales of the underlying commencing on 10/21/2026
Date of Notice	10/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Edward Michael Kaye
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)